Data / Drug companies / Trigen Laboratories, LLC
Trigen Laboratories, LLC: 31 products in the FDA NDC directory, labeler code 13811
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Trigen Laboratories, LLC (labeler code 13811) lists 31 products in the FDA National Drug Code Directory, covering 8 finished drugs by generic name. By type: 31 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on June 30, 2025.
The request: Watch Trigen Laboratories, LLC (FDA labeler code 13811): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 13811
- Products in commercial distribution
- 31
- Packages
- 46
- Finished drugs by generic name
- 8
- Prescription products
- 31
- Over the counter products
- 0
- Controlled substance products
- Schedule II 11, Schedule IV 12, Schedule V 1
- Flagged as original packager
- 31 of 31 products that carry the flag
- Started marketing in the last 12 months
- 0
- Products with a marketing end date set
- 1
- Earliest marketing start
- April 29, 2010
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 11 | 35.5% |
| Other unapproved drugs | 9 | 29% |
| Authorized generics (NDA) | 6 | 19.4% |
| New drug applications (NDA) | 5 | 16.1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 31 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Phenobarbital | 9 | 25 |
| Methylphenidate hydrochloride | 7 | 39 |
| Estradiol | 5 | 53 |
| Hydromorphone hydrochloride | 4 | 20 |
| Tramadol hydrochloride | 3 | 44 |
| Nitrofurantoin | 1 | 28 |
| Lacosamide | 1 | 57 |
| Venlafaxine hydrochloride | 1 | 48 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, extended release | 12 | 38.7% |
| Tablet | 8 | 25.8% |
| Gel | 5 | 16.1% |
| Capsule | 4 | 12.9% |
| Injection | 1 | 3.2% |
| Elixir | 1 | 3.2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Opioid Agonist | 7 |
| Central Nervous System Stimulant | 7 |
| Estrogen | 5 |
| Nitrofuran Antibacterial | 1 |
| Serotonin and Norepinephrine Reuptake Inhibitor | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Lacosamide | 13811-207 | Injection | Generic drugs (ANDA) | June 30, 2025 |
| Phenobarbital | 13811-299 | Elixir | Other unapproved drugs | May 5, 2025 |
| Phenobarbital | 13811-307 | Tablet | Other unapproved drugs | April 1, 2025 |
| Phenobarbital | 13811-306 | Tablet | Other unapproved drugs | April 1, 2025 |
| Phenobarbital | 13811-305 | Tablet | Other unapproved drugs | April 1, 2025 |
| Phenobarbital | 13811-304 | Tablet | Other unapproved drugs | April 1, 2025 |
| Phenobarbital | 13811-303 | Tablet | Other unapproved drugs | April 1, 2025 |
| Phenobarbital | 13811-302 | Tablet | Other unapproved drugs | April 1, 2025 |
| Phenobarbital | 13811-301 | Tablet | Other unapproved drugs | April 1, 2025 |
| Phenobarbital | 13811-300 | Tablet | Other unapproved drugs | April 1, 2025 |
| Estradiol | 13811-094 | Gel | New drug applications (NDA) | October 10, 2022 |
| Estradiol | 13811-093 | Gel | New drug applications (NDA) | October 10, 2022 |
| Estradiol | 13811-092 | Gel | New drug applications (NDA) | October 10, 2022 |
| Estradiol | 13811-091 | Gel | New drug applications (NDA) | October 10, 2022 |
| Estradiol | 13811-090 | Gel | New drug applications (NDA) | October 10, 2022 |
| Methylphenidate Hydrochloride | 13811-711 | Tablet, extended release | Authorized generics (NDA) | June 23, 2022 |
| Methylphenidate Hydrochloride | 13811-700 | Tablet, extended release | Authorized generics (NDA) | June 23, 2022 |
| Nitrofurantoin | 13811-719 | Capsule | Generic drugs (ANDA) | January 1, 2018 |
| Methylphenidate Hydrochloride | 13811-710 | Tablet, extended release | Generic drugs (ANDA) | December 29, 2017 |
| Methylphenidate Hydrochloride | 13811-709 | Tablet, extended release | Generic drugs (ANDA) | August 14, 2017 |
| Methylphenidate Hydrochloride | 13811-708 | Tablet, extended release | Generic drugs (ANDA) | August 14, 2017 |
| Methylphenidate Hydrochloride | 13811-707 | Tablet, extended release | Generic drugs (ANDA) | August 14, 2017 |
| Methylphenidate Hydrochloride | 13811-706 | Tablet, extended release | Generic drugs (ANDA) | August 14, 2017 |
| Hydromorphone Hydrochloride | 13811-704 | Tablet, extended release | Generic drugs (ANDA) | September 15, 2016 |
| Hydromorphone Hydrochloride | 13811-703 | Tablet, extended release | Generic drugs (ANDA) | September 15, 2016 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.